Drug Trial Radar · NCT05311215
Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity
Last checked: Nov 19, 2026Latest source record: Sep 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
32
Planned (sponsor's estimate)
Start
Apr 22, 2022
Primary completion
Sep 2023
Study completion Sep 2023
Sponsor
- Lead sponsor
- Saol Therapeutics IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled single ascending dose escalation study intended to assess the safety, pharmacokinetics and efficacy of single treatment of SL-1002 in patients with mild to severe limb spasticity. The study will enroll 4 cohorts of 8 patients per cohort for a total of 32 patients. Patients will be randomized to receive either SL-1002 or placebo in a 3:1 ratio. The study period will be up to 26 weeks inclusive of a screening period of up to 2 weeks.
Conditions
- Spasticity
Interventions
SL-1002Drug
SL-1002 injectable solution
PlaceboDrug
Matching placebo injectable solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of treatment emergent adverse events (TEAEs) overallTime frame: time of study drug administration to end of study visit (day 168)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
TIRR Memorial Hermann Research Center
Houston, Texas
Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.